
Mr. Gunjan Singh, VP & Head (Europe & U.S.), API Sales and Marketing at Dr. Reddys API, shared profound insights at the recent summit themed "Making India a Global Pharma and Lifesciences Innovation Hub." His comprehensive coverage included pivotal topics such as evolving business models, bridging academia-industry gaps, fermenting technology for robust API manufacturing, enforcing the new Schedule M, and fostering a new Indian vaccine ecosystem.
Gunjan Singh emphasized India's potential for self-sufficiency in API and outlined strategies for achieving cost competitiveness. Intellectual property rights were underscored as a key focus area for long-term results. His invaluable recommendations have garnered widespread appreciation from participants and stakeholders within the Pharma and Biotech industry.
The summit witnessed the convergence of senior Government officials, policymakers, key industry experts, innovators, and academicians. Together, they deliberated to propel India into an Innovation Hub in the Lifesciences Sector.
Mr. Gunjan Singh's contribution at the summit marks a significant step forward in shaping the future of India's Pharma and Biotech landscape. The collaborative efforts showcased the nation's commitment to becoming a global leader in Lifesciences innovation.
Media Coverage Click here.
本網站上的任何信息,包括對任何產品或服務的任何提及,均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是,在某些情況下,雷迪博士可自行決定並根據當地法律要求,在存在此類監管豁免的任何地方,提供此類產品的研究數量,以根據《印度專利法》第 107A 條(Bolar 豁免)進行監管提交。購買者應對其各自市場的產品或服務(包括專利情況)進行獨立評估,並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證,包括但不限於適銷性、適用於特定用途和非侵權的保證。